Welcome to our dedicated page for Quantum BioPharma news (Ticker: QNTM), a resource for investors and traders seeking the latest updates and insights on Quantum BioPharma stock.
Quantum BioPharma Ltd (QNTM) is a biopharmaceutical innovator developing therapies for neurodegenerative, neuropsychiatric, and inflammatory disorders. This page aggregates official news and press releases about the company’s clinical advancements, strategic investments, and market-related developments.
Investors and industry observers will find timely updates on clinical trial progress, regulatory milestones, and strategic financial decisions, including partnerships or legal initiatives impacting shareholder value. The curated content spans research breakthroughs, intellectual property updates, and balanced coverage of both pharmaceutical R&D and complementary investment activities.
All content is sourced directly from company communications to ensure accuracy. Visitors can expect coverage of FDA trial phases, compound licensing deals, and portfolio management decisions from Quantum BioPharma’s dual operational segments. Bookmark this page for efficient tracking of material events affecting QNTM’s trajectory in the biotech sector.
Quantum BioPharma (NASDAQ: QNTM) has received a Product License (PN 80144141) from Health Canada for Qlarity™, its innovative natural health product. The license allows Quantum to market Qlarity in Canada with approved claims for enhancing energy production, metabolism, mental alertness, and cognitive performance.
The company has already licensed a similar product in the United States under the brand name unbuzzd™. This regulatory approval marks a significant milestone in Quantum's strategy to expand its portfolio of innovative biotech solutions for neurodegenerative and metabolic disorders.
Quantum BioPharma (NASDAQ: QNTM) announced that its licensee, Unbuzzd Wellness, will host an investor webinar on September 16, 2025, at 1:30 PM PT. The webinar will feature presentations from key executives including CEO John Duffy, discussing their scientifically-proven beverage that accelerates alcohol metabolism and reduces hangover symptoms.
The webinar will focus on Unbuzzd's Regulation D 506(c) offering aiming to raise up to $5.0 million to support expansion plans and a possible IPO. Company leaders will present clinical study results, growth strategies, and plans for direct-to-consumer, distributor, and retail sales. Importantly, Quantum BioPharma shareholders will not face dilution from this offering.
Quantum BioPharma (NASDAQ: QNTM) has received analyst coverage initiation from Kingswood Capital Partners with a BUY rating and US$45 price target. The valuation is based on a discounted cash flow analysis assuming successful Phase 2 and 3 trials of Lucid-MS during 2026-2028, with anticipated commercial launch in 2029.
The coverage is led by Karen Sterling, PhD, CFA, Senior Equity Analyst at Kingswood Capital Partners. Notably, this is unpaid research with no consideration provided by Quantum BioPharma, which is developing innovative solutions for neurodegenerative, metabolic, and alcohol misuse disorders.
Quantum BioPharma (NASDAQ: QNTM), a biopharmaceutical company focused on neurodegenerative and metabolic disorders, announced several corporate updates. The company settled $26,812.50 USD in debt through the issuance of 1,102 Class B Shares at $24.33 USD per share.
The Board granted 800 RSUs each to Clinical Advisors Peter Stys and Jack Antel, with vesting tied to regulatory milestones for Lucid MS clinical trials. Additionally, Kevin Malone's Board Advisor Agreement was terminated effective August 15, 2025.
Quantum BioPharma (NASDAQ: QNTM) has announced updates regarding its previously disclosed non-brokered private placement. The company will seek shareholder approval for the offering of class A multiple voting shares (MVS) at its upcoming annual general meeting on September 26, 2025. The private placement aims to raise gross proceeds of up to $600.
The offering is expected to be primarily subscribed by existing MVS holders and will include a statutory hold period of four months plus one day. The proceeds will be used for general working capital purposes. The securities being offered will not be registered under the U.S. Securities Act of 1933 and cannot be sold in the United States without registration or exemption.
["Company is raising additional working capital through private placement", "Existing MVS holders expected to participate, showing continued investor confidence"]Quantum BioPharma (NASDAQ: QNTM) has signed an agreement with a leading CDMO to manufacture an oral formulation of Lucid-MS (Lucid-21-302) for its upcoming Phase 2 clinical trial in multiple sclerosis treatment.
Lucid-MS is a first-in-class, non-immunomodulatory, neuroprotective compound designed to prevent demyelination, a characteristic feature of MS. The drug has shown promising results in animal models over the past decade, demonstrating potential in helping subjects regain walking ability. The oral formulation development represents a crucial step as the company prepares its Investigational New Drug (IND) application with the FDA.
Quantum BioPharma (NASDAQ: QNTM) announced promising results from Massachusetts General Hospital (MGH) scientists regarding a novel PET tracer [18F]3F4AP for detecting and monitoring demyelination in Multiple Sclerosis (MS) patients. The study, published in the European Journal of Nuclear Medicine and Molecular Imaging, demonstrated the tracer's ability to detect differences across MS lesions not visible through conventional MRI.
Led by Drs. Pedro Brugarolas and Eric Klawiter at MGH and funded by NIH, the research revealed the tracer's excellent properties for brain imaging. This breakthrough could be particularly significant for monitoring the effectiveness of Quantum's investigational MS drug, Lucid-21-302, in protecting the myelin sheath in MS patients.
Quantum BioPharma (NASDAQ: QNTM) reported strong Q2 2025 results, highlighting significant financial and operational achievements. The company's total current assets increased to $10.3 million USD from $9.9 million in Q1, with total assets reaching $15.3 million USD. Notable achievements include the conversion of all debentures into equity, cryptocurrency gains exceeding $500,000 USD, and a stock price surge from $7.71 to $20.25 USD during Q2.
The company's clinical progress includes positive toxicity studies for Lucid-MS, their multiple sclerosis drug candidate, and a breakthrough PET scan imaging study with Massachusetts General Hospital. Additionally, their alcohol metabolism product unbuzzd, licensed to Unbuzzd Wellness Inc., is advancing with a $5.0 million USD Regulation D offering and potential IPO plans.
Management projects sufficient cash for operations beyond March 2027, with operating expenses at $4.9 million USD in Q2, up from $3.4 million in Q1.
Quantum BioPharma (NASDAQ: QNTM) has announced positive results from its Phase 1 Multiple Ascending Dose (MAD) clinical trial for Lucid-MS, their experimental multiple sclerosis drug. The Clinical Study Report (CSR) confirms that Lucid-MS demonstrated safety and tolerability in healthy participants with consecutive daily dosing.
Lucid-MS is a first-in-class, non-immunomodulatory, neuroprotective compound designed to prevent demyelination, a characteristic feature of multiple sclerosis. The successful completion of this trial and CSR marks a crucial milestone, enabling the company to proceed with its Investigational New Drug (IND) application to the FDA and advance toward efficacy trials in MS patients.
Quantum BioPharma (NASDAQ: QNTM) has filed a memorandum of law opposing CIBC World Markets and RBC Dominion Securities' joint motion to dismiss in the Southern District of New York. The lawsuit alleges that the defendants engaged in market manipulation through "spoofing" between January 2020 and August 2024, seeking damages exceeding $700 million USD.
The company claims its stock traded above $460 USD per share in January 2020 with a market cap approaching $1 billion before being artificially depressed. Law firms Christian Attar and Freedman Normand Friedland LLP are handling the case on a contingency basis, eliminating material financial pressure on Quantum. The company suggests other banks may be involved but will refrain from naming them until gathering more conclusive evidence.
FAQ
What is the current stock price of Quantum BioPharma (QNTM)?
What is the market cap of Quantum BioPharma (QNTM)?
